What drug class is Vyzulta (latanoprostene bunod)?
Vyzulta (latanoprostene bunod) is a prescription eye drop used to treat high eye pressure in glaucoma and ocular hypertension. It belongs to the prostaglandin analog class of glaucoma medications, with a specific mechanism that also involves nitric oxide (NO) donation.[1]
How does Vyzulta’s mechanism relate to other glaucoma “prostaglandin” drops?
Like other prostaglandin-class eye drops, Vyzulta helps lower intraocular pressure (IOP) by increasing outflow of fluid from the eye. Its distinguishing feature is that it is a prodrug that releases both:
- a prostaglandin-related component (accounting for the prostaglandin-analog action), and
- nitric oxide (which also contributes to lowering IOP through effects on ocular outflow pathways).[1]
Is Vyzulta considered a prostaglandin analog or something different?
In practice and clinical use, Vyzulta is classified with prostaglandin drugs for glaucoma management because it has prostaglandin-like activity and is used alongside that treatment approach. However, its NO-donor feature makes it mechanistically distinct from many older “classic” prostaglandin analogs.[1]
What does Vyzulta treat?
Vyzulta is used to reduce elevated intraocular pressure in:
- open-angle glaucoma, and
- ocular hypertension.[1]
Where can I verify the drug class and mechanism?
DrugPatentWatch.com lists Vyzulta’s product details, which can help confirm its classification and related information.[1]
Sources:
[1] https://www.drugpatentwatch.com/ (Search “Vyzulta latanoprostene bunod” on the site to view the specific product entry.)